A polymorphism at the 3'-UTR region of the aromatase gene is associated with the efficacy of the aromatase inhibitor, anastrozole, in metastatic breast carcinoma.
about
The Association of CYP19A1 Variation with Circulating Estradiol and Aromatase Inhibitor Outcome: Can CYP19A1 Variants Be Used to Predict Treatment Efficacy?Genetic polymorphisms in estrogen-related genes and the risk of breast cancer among Han Chinese women.The CYP19 RS4646 polymorphism IS related to the prognosis of stage I-II and operable stage III breast cancerInfluence of CYP19A1 polymorphisms on the treatment of breast cancer with aromatase inhibitors: a systematic review and meta-analysis.Genetic polymorphism at Val80 (rs700518) of the CYP19A1 gene is associated with body composition changes in women on aromatase inhibitors for ER (+) breast cancer.S4646 polymorphism in CYP19A1 gene is associated with the efficacy of hormone therapy in early breast cancer.CYP19A1 polymorphisms and clinical outcomes in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial.Association of CYP8A1 (Prostacyclin I2 synthase) polymorphism rs5602 with breast cancer in Mexican woman.The rs4646 and rs12592697 Polymorphisms in CYP19A1 Are Associated with Disease Progression among Patients with Breast Cancer from Different Racial/Ethnic Backgrounds.Polymorphisms in drug-metabolizing enzymes and steady-state exemestane concentration in postmenopausal patients with breast cancer.Predictive markers in elderly patients with estrogen receptor-positive breast cancer treated with aromatase inhibitors: an array-based pharmacogenetic study.Pharmacogenetics and aromatase inhibitor induced side effects in breast cancer patients.Germline genetic predictors of aromatase inhibitor concentrations, estrogen suppression and drug efficacy and toxicity in breast cancer patients.The implications of genetic variation for the pharmacokinetics and pharmacodynamics of aromatase inhibitors.Rs1008805 polymorphism of CYP19A1 gene is associated with the efficacy of hormone therapy in stage I-II and operable stage III breast cancer.
P2860
Q30234511-BE2E248F-9BFB-4EF5-816D-A7630097C6E8Q35139194-EAE28D3A-756E-42F1-86A9-97D514296003Q35202833-6D585A68-CBC6-4E49-891C-6CC190CB67C7Q35661622-DD70DBA3-08A3-41B1-8270-420E95CF76D7Q35842073-3ED78244-A44E-496D-8437-A3DE86361E76Q35854143-BBD10916-6871-45E0-A1D4-821CC3A5CA59Q36606068-4161602E-3745-44CC-AFEA-94F371EE246FQ36878734-E5CA2766-EC3A-4E89-9448-E8E170903487Q37463634-33FBD130-E1EC-4536-B2C2-4E4181B9E04AQ37662607-A2682B73-26C6-407F-9751-5136FCBCE2BBQ38295718-383D5ED4-7E5B-465A-B0B0-D5C8C1671A87Q38737784-F74B00BD-49BC-4E96-9BED-1B2FFD2984FCQ38739248-80FF4F78-46FE-468D-8590-7E78038D67C5Q38851505-99CBF632-0A0D-4D18-9DAA-BA8E81DE36A5Q44502008-3FA01AF9-0EAA-4E8F-A8CF-9EBEABFA6009
P2860
A polymorphism at the 3'-UTR region of the aromatase gene is associated with the efficacy of the aromatase inhibitor, anastrozole, in metastatic breast carcinoma.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 13 September 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
A polymorphism at the 3'-UTR r ...... n metastatic breast carcinoma.
@en
A polymorphism at the 3'-UTR r ...... n metastatic breast carcinoma.
@nl
type
label
A polymorphism at the 3'-UTR r ...... n metastatic breast carcinoma.
@en
A polymorphism at the 3'-UTR r ...... n metastatic breast carcinoma.
@nl
prefLabel
A polymorphism at the 3'-UTR r ...... n metastatic breast carcinoma.
@en
A polymorphism at the 3'-UTR r ...... n metastatic breast carcinoma.
@nl
P2093
P2860
P356
P1476
A polymorphism at the 3'-UTR r ...... n metastatic breast carcinoma.
@en
P2093
Heng-Heng Yuan
Jian-Hua Zhou
Jing-Xuan Wang
Peng Huang
Qing-Yuan Zhang
Ting-Ting Zhang
P2860
P304
18973-18988
P356
10.3390/IJMS140918973
P407
P577
2013-09-13T00:00:00Z